Key terms
About CHRS
Coherus BioSciences, Inc. is a commercial-stage biopharmaceutical company, which engages in the development and commercialization of biosimilar therapeutics. Its products include UDENYCA and Coherus COMPLETE. The company was founded by Dennis M. Lanfear, Stuart E. Builder, Dr. Alan Herman, Doug Farrar and Steve Glover in September 2010 and is headquartered in Redwood City, CA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest CHRS news
Apr 15
4:30am ET
Analysts Offer Insights on Healthcare Companies: 4D Molecular Therapeutics (FDMT), Acadia Healthcare (ACHC) and Coherus Biosciences (CHRS)
Apr 08
8:50am ET
Coherus data show CHS-1000 acts to reverse myeloid suppression
Mar 20
6:16am ET
Buy Rating on Coherus Biosciences: Balancing Divestiture with Promising Pipeline and Financial Growth
Mar 20
6:06am ET
Coherus Biosciences price target lowered to $11 from $13 at H.C. Wainwright
Mar 14
8:30pm ET
Analysts Offer Insights on Healthcare Companies: Coherus Biosciences (CHRS) and Solid Biosciences (SLDB)
Mar 14
1:40pm ET
Analysts Offer Insights on Healthcare Companies: Cullinan Management (CGEM), Coherus Biosciences (CHRS) and Autolus Therapeutics (AUTL)
Mar 14
7:30am ET
Analysts Conflicted on These Healthcare Names: Amedisys (AMED), Cytokinetics (CYTK) and Coherus Biosciences (CHRS)
Mar 14
6:15am ET
Buy Rating Affirmed for Coherus Biosciences on Strong Sales and Strategic Restructuring
Mar 13
4:11pm ET
Coherus Biosciences reports Q4 EPS (62c), consensus (12c)
Mar 13
2:49pm ET
Coherus BioSciences options imply 21.5% move in share price post-earnings
Mar 13
8:05am ET
Options Volatility and Implied Earnings Moves Today, March 13, 2024
Mar 04
6:35am ET
Sandoz acquires CIMERLI business from Coherus BioSciences
Feb 22
5:13pm ET
Coherus Biosciences Appoints New Director, Boosts Governance
Feb 21
8:31am ET
Coherus Biosciences announces U.S. launch of UDENYCA ONBODY
Feb 06
4:22am ET
Coherus Biosciences Announces Key Consent and Amendment
Feb 06
4:21am ET
Coherus Biosciences Amends Loan Terms with Biopharma
Feb 05
8:20am ET
Coherus Biosciences amends term loan agreement with Pharmakon
Jan 29
5:07am ET
Barclays Sticks to Their Buy Rating for Coherus Biosciences (CHRS)
Jan 25
11:38am ET
Biotech Alert: Searches spiking for these stocks today
Jan 25
11:38am ET
Biotech Alert: Searches spiking for these stocks today
Jan 24
11:08am ET
Biotech Alert: Searches spiking for these stocks today
Jan 23
9:17am ET
Coherus Biosciences price target lowered to $8 from $12 at Truist
Jan 23
6:15am ET
Coherus Biosciences price target lowered to $9 from $11 at Baird
Jan 23
3:09am ET
Coherus Biosciences Announces New Purchase Agreement Details
Jan 23
3:09am ET
Coherus BioSciences Sells CIMERLI® Franchise to Sandoz
Jan 22
3:17pm ET
Promising Clinical Advances and Market Potential Uphold Buy Rating for Coherus Biosciences
Jan 22
2:42pm ET
Barclays Gives a Buy Rating to Coherus Biosciences (CHRS)
Jan 22
1:29pm ET
Buy Rating Affirmed for Coherus Biosciences on Strong Clinical Data and Strategic Pipeline Positioning
Jan 22
7:03am ET
Coherus (NASDAQ:CHRS) Surges After $170M Deal with Sandoz for CIMERLI Franchise
Jan 22
6:35am ET
Sandoz agrees to acquire Cimerli business from Coherus
Jan 18
4:28pm ET
Coherus Biosciences presents positive Phase 2 data on casdozokitu
No recent press releases are available for CHRS
CHRS Financials
Key terms
Ad Feedback
CHRS Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
CHRS Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range